Shandong Boan Biotechnology Co. Ltd., a joint stock company based in the People's Republic of China, has announced the placement of 38,400,000 new shares under a general mandate. This represents approximately 7.17% of the company's total shares in issue. The company has entered into an agreement with a Placing Agent to facilitate the sale of these new shares on a best effort basis. The initiative is part of the company's strategy to raise capital and strengthen its financial position. The shares are listed on the Main Board of the Stock Exchange of Hong Kong, under the stock code 6955.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。